Speakers' Portal IGCS18 CME Disclosure Form Results

Last Name	First Name	Roles	Relationships	Company Name	Honoraria/ Expenses	Consulting/ Advisory Board	<u>Funded</u> <u>Research</u>	Royalties/ Patent	Stock Options	Ownership/ Equity Position	Employee	<u>Other</u>	Off Label Product Use
Abu-Rustum	Nadeem	Invited Speaker/Faculty Session Moderator/Chair/Coordinator Board of Directors	No			Doura				rosidon			
Adams	Tracey	Session Moderator/Chair/Coordinator	No										
Adams	Catherine	Invited Speaker/Faculty	No										
Amant	Frederic	Invited Speaker/Faculty	No										
Arimoto	Takahide	Invited Speaker/Faculty	No										
		Poster/Oral Presenter											
Asada	Kayo	Invited Speaker/Faculty Poster/Oral Presenter	No										
Bacon	Monica	Invited Speaker/Faculty	No										
Baiocchi	Glauco	Invited Speaker/Faculty Poster/Oral Presenter	No										
Baker	Ellen	Invited Speaker/Faculty	No										
Becker	Sven	Invited Speaker/Faculty Poster/Oral Presenter	No										
Berek	Jonathan S.	Invited Speaker/Faculty Session Moderator/Chair/Coordinator	Yes	Tesaro			х						
Binagwaho	Agnes	Invited Speaker/Faculty	No										
Brand	Alison	Invited Speaker/Faculty	No										
Brennan	Donal	Session Moderator/Chair/Coordinator	No										
Chiang	Sarah	Invited Speaker/Faculty	No										
Cohen	Paul	Scientific/Education Planning Committee Invited Speaker/Faculty Session Moderator/Chair/Coordinator	No										
Coleman	Robert L	Scientific/Education Planning Committee Invited Speaker/Faculty Session Moderator/Chair/Coordinator Poster/Oral Presenter	Yes	AstraZeneca	х	х	x						bevacizumab, PARPi, Immunotherapies, Mirvetuximab and other novel therapeutics
				Eisai	x	x	x						bevacizumab, PARPi, Immunotherapies, Mirvetuximab and other novel therapeutics
				Genentech	x	х	x						bevacizumab, PARPi, Immunotherapies, Mirvetuximab and other novel therapeutics
				Janssen Pharmaceuticals	x	x	x						bevacizumab, PARPi, Immunotherapies, Mirvetuximab and other novel therapeutics
				Novartis	x	x							bevacizumab, PARPi, Immunotherapies, Mirvetuximab and other novel therapeutics
				Tesaro		х							bevacizumab, PARPi, Immunotherapies, Mirvetuximab and other novel therapeutics
				Abbvie		х	х						bevacizumab, PARPi, Immunotherapies, Mirvetuximab and other novel therapeutics
				Clovis	х	х	х						bevacizumab, PARPi, Immunotherapies, Mirvetuximab and other novel therapeutics

											bevacizumab, PARPi, Immunotherapies,
				Merck		X	X				Mirvetuximab and other
									-		novel therapeutics
											bevacizumab, PARPi,
				Genmab	X	X	X				Immunotherapies,
											Mirvetuximab and other
											novel therapeutics
Covens	Allan	Scientific/Education Planning Committee	No								
		Invited Speaker/Faculty									
		Session Moderator/Chair/Coordinator									
		Poster/Oral Presenter									
Creutzberg	Carien	Scientific/Education Planning Committee	No								
		Invited Speaker/Faculty									
		Session Moderator/Chair/Coordinator									
Dizon	Don	Invited Speaker/Faculty	No								
	Greta	Invited Speaker/Faculty									
Dreyer	Greta		No								
		Poster/Oral Presenter									
Duska	Linda	Invited Speaker/Faculty	No								
Eskander	Ramez	Invited Speaker/Faculty	Yes	AstraZeneca	X	X					
				Genentech	X	X					
				Clovis Oncology	X	X					
Ferron	Gwenaël	Invited Speaker/Faculty	No								
Fleming	Gini	Invited Speaker/Faculty	Yes			1					letrozole/everolimus for
cg	J	Session Moderator/Chair/Coordinator									endometrial cancer.
		5555011 WOGET GLOT/OTTGIT/OUDTGITGLOT									other endometrial cancer
				Cornent							
				Corcept			X				therapeutics (almost
											nothing is on label for
											endometrial cancer)
Frumovitz	Michael	Invited Speaker/Faculty	Yes	Stryker	X	X	X				
				Navidea			X				
				Genentech		X					
Fujii	Shingo		No								
Fujiwara	Noriko	Invited Speaker/Faculty	No						T T		
Fujiwara	Hiroyuki	Invited Speaker/Faculty	No						T T		
Fujiwara	Keiichi	Scientific/Education Planning Committee	Yes	AstraZeneca	Х	X	Х				
i ujiwala	I COILOI II	Invited Speaker/Faculty	100	Daiichi Sankyo	X	X	X				
		Session Moderator/Chair/Coordinator		Eisai	X	X	X	-	-	-	
				Janssen Pharmaceuticals	X				-		
				Merck		X	X				
				Pfizer		X	X				
				Takeda		X					
				Ono Pharmaceuticals		X	X				
				Zeria	Х		X				
				Chugai Roche	X						
				Kyowahakko-Kirin	X	1					
Gardner	Ginger	Invited Speaker/Faculty	No	,							
Garano	Onigoi	Session Moderator/Chair/Coordinator	140								
Corrett	Andrea		No								
Garrett		Invited Speaker/Faculty									
Gerda Zahl	Ane	Session Moderator/Chair/Coordinator	No								
Eriksson											
Gershenson	David	Invited Speaker/Faculty	Yes								aromatase inhibitors,
		Session Moderator/Chair/Coordinator									tamoxifen, leuprolide
				celgene						X	acetate, MEK inhibitors,
											CDK 4/6 inhibitors
									T T		aromatase inhibitors,
											tamoxifen, leuprolide
				Johnson&Johnson						X	acetate, MEK inhibitors,
				JUINSUNGSUNISUN						^	CDK 4/6 inhibitors
											CDK 4/6 ITITIDILOTS
											aromatase inhibitors,
											aromatase inhibitors, tamoxifen, leuprolide
				Di · ·						.,	
				Biogen Idec						Х	acetate, MEK inhibitors,
				Biogen Idec						х	

Claric Chrostogy X Claric Chrostogy X Claric Chrostogy X Claric Chrostogy A Bisecer X Claric Chrostogy Bisecer X Claric Chrostogy CLC 48 in bittors CL													
Eberore X CICK 45 mitters Up1 Coloria VX CICK 45 mitters Secondary Finally VX CICK 45 mitters CICK 45 mitters VX CICK 45 mitters CICK 45 mitters VX CICK 45 mitters						Obstite Outstand		V					tamoxifen, leuprolide
Eisevier X X executive for the control of the contr						Clovis Oncology		X					
Ut To Determine State of Tourist Control of Tourist State													tamoxifen, leuprolide
UT NO Archaroz Cincer UT NO Archaroz Cincer Conter Noticined Camer instable (NRG Overlopp) Noticined Camer instable (NRG Overlopp) Contry Charie Serviced Speaked Faulty Ves AddraZeneck X X X Armitted Content Armitted Speaked Faulty Service (Armitted Spea						Elsevier				X			
Lip Tockside UT MD Anderson Cancer Content UT MD Anderson Cancer Content Noticed Greater Frontier (NRC O Oncology) A monitor Separated Frontier Noticed Greater Frontier Note Greate													
UT IND Anderson Cencer Center National Center Institute (WRG Problety) Gaile Bake Invited Speaked Flourity No Corted Walter Invited Speaked Flourity No Corted Speaked Flourity No Courtey Charlie Courtey Charlie Courtey Charlie Genetisch A AndraZeroca X X X Session Moderson/Chair/Coordinater AstroaZeroca X X X Genetisch A number of possible agent for investigation in the treatment of size. The same of possible agent for investigation in control of the specifying in the distance of possible agent for investigation in the specifying A number of possible agent for investigation in the specifying A number of possible agent for investigation in the specifying A number of possible agent for investigation in the specifying A number of possible agent for investigation in the specifying Individual coolace. A number of possible agent for investigation in the specifying Individual coolace. A number of possible agent for investigation in the specifying Individual coolace.						UpToDate				Х			acetate, MEK inhibitors,
Cerear Control Speaker Faculty National Cancer Institute (NRS Onesdegry) National Cancer Institute (NRS Onesdegry) X						LIT MD Anderson Conser							tamoxifen, leuprolide
National Cancer restitute												X	
(NRG Oncology) Gilks Blake Invited Speaker/Facuity No AstraZeroca X X X Gouley Chanie Invited Speaker/Facuity Yes AstraZeroca X X X Gourley Chanie Scentific-Education Planning Committee Invited Speaker/Facuity Session Moderator/Chair/Coordinator AstraZeroca X X X X AstraZeroca X X X X Generator X X X Gen						National Canaar Institute							
Cotation Walter Invited Speaker/Facually Earned of Directors									X				
Cottlete Walter Invited Speaker/Faculty Eard of Directors	Gi	lks Blai	ke	Invited Speaker/Faculty	No								
Invited Speaker/Faculty Session Moderator/Chair/Coordinator AstraZeneca X X X X X Session Moderator/Chair/Coordinator AstraZeneca X X X X X Session Moderator/Chair/Coordinator AstraZeneca X X X X X Session Moderator/Chair/Coordinator Invited Speaker Session Moderator/Chair/Coordinator AstraZeneca X X X X Session Moderator/Chair/Coordinator Invited Speaker Session Se	Got	lieb Wal	ter	Invited Speaker/Faculty Board of Directors	Yes	AstraZeneca		Х	Х				
Session Moderator/Chair/Coordinator AstraZeneca X X X X end of case of call ovarian cancer, these will be discussed largely as drug classed largely as drug classed largely as drug classed and the transment of case	Gou	irley Cha	rlie		Yes								
these will be discussed largely as drug classes rather than specifying individual forducts. A round or of possible in the control of the con													
Tesaro X X X X Individual products. A number of possible agents for investigation in the treatment of clear of the treatment of clear of the treatment of the						AstraZeneca .	×	×	x				
rather than specifying individual products. A number of possible agents of the description in the treatment of clear cell ovarian cancer, these will be discussed in a cell ovarian cancer, and the specifying individual products. A number of possible agents of investigation in the treatment of clear cell ovarian cancer, these will be discussed in a cell ovarian cancer, and the specific of investigation in the treatment of cell ovarian cancer, the specific of investigation in the treatment of cell ovarian cancer, these will be discussed largely as drug classes rather than specifying individual products. Tesaro X X X Tesaro X X X X X X Tesaro X X X X X X Tesaro X X X X X X													
A number of possible agents for investigation in the treatment of clear cell ovarian cancer, these will be discussed largely as drug disasses individual products. A number of possible agents for investigation in the treatment of clear cell ovarian cancer, the control of the													
agents for investigation in the treatment of clear cell ovarian cancer; these will be discussed largely as drug classes are cell ovarian cancer; the cell ovarian cancer; these will be discussed and the cell ovarian cancer; the cell ovarian cancer													individual products.
Genentech X X X in the treatment of clear cell ovarian cancer; these will be discussed largely as drug classes rather than specifying individual products. Nucana X X X X Nucana X X X X Reserved that support the served surgely as drug classes and served surgely as drug classes are served surg													
these will be discussed largely as drug diases rather than specifying individual products. A number of possible agents for investigation in the treatment of clear call or agents for investigation in the treatment of clear rather than specifying individual products. Nucana X X X X Nucana X X X X X X Nucana X X X X X X X X Nucana X X X X X X X X X X X X X X X X X X													
nesse will ce discussed largely as drug classes rather than specifying individual products. A number of possible agents for investigation in the treatment of clear clear cell ovarian cancer; these will be discussed largely as drug classes. Tesaro X X X X Tesaro X X X Tesaro X X X X X Tesaro X X X X Tesaro X X X X Tesaro X X X X X X X X Tesaro X X X X X X X X X X X X X X X X X X X						Genentech	×	×					
Tesaro X X X Tesaro X X X X X X X Tesaro X X X X X X X X X X X X X X X X X X X						Continuon	,	,					
Nucana X X X X Anumber of possible agents for investigation in the treatment of clear cell ovarian cancer; these will be discussed alargely as drug classes rather than specifying individual products. A number of possible agents for investigation in the treatment of clear cell ovarian cancer; these will be discussed agents for investigation in the treatment of clear cell ovarian cancer; these will be discussed largely as drug classes rather than specifying individual products. A number of possible agents for investigation in the treatment of clear cell ovarian cancer; these will be discussed largely as drug classes rather than specifying individual products. A number of possible agents for investigation in the treatment of clear cell ovarian cancer; these will be discussed largely as drug classes rather than specifying individual products. Novartis X telephosphore cell ovarian cancer; the discussed largely as drug classes rather than specifying agents for investigation in the treatment of clear cell ovarian cancer; the set of the control of the cell ovarian cancer; the set of the cell ovarian cancer; t													
Nucana X X X X S S S S S S S S S S S S S S S													individual products.
Nucana X X X X X S STAND													
Nucana X X X X S STATE CALL OF THE PROPERTY OF													
these will be discussed largely as full classes rather than specifying individual products. A number of possible agents for investigation in the treatment of clear cell ovarian cancer, these will be discussed largely as drug classes rather than specifying individual products. Novartis X these will be discussed agents for investigation in the treatment of clear cell ovarian cancer, and the specified in the treatment of clear cell ovarian cancer; these will be discussed largely as drug classes rather than specifying in the treatment of clear cell ovarian cancer; these will be discussed largely as drug classes rather than specifying ovariance cancer; these will be discussed largely as drug classes rather than specifying and the control of the control ovariance cancer; these will be discussed largely as drug classes rather than specifying and control ovariance cancer; the control ovariance cancer; these will be discussed largely as drug classes rather than specifying and control ovariance cancer.						Nucana	×	×	Y				cell ovarian cancer;
Tesaro X X X X Tesaro X X X X X Tesaro X X X X X Tesaro X X X X X X Tesaro X X X X X X X X X Tesaro X X X X X X X X X X X X X X X X X X X						radana	,	,	,				
individual products. A number of possible agents for investigation in the treatment of clear cell ovarian cancer; these will be discussed largely as drug classes rather than specifying individual products. Novartis X individual products. A number of possible agents for investigation in the treatment of clear cell ovarian cancer; these will be discussed largely as drug classes rather than specifying individual products. A number of possible agents for investigation in the treatment of clear cell ovarian cancer; these will be discussed largely as drug classes are greater than specifying the discussed largely as drug classes are greater than specifying the discussed largely as drug classes are greater than specifying the discussed largely as drug classes are greater than specifying the discussed largely as drug classes are greater than specifying the discussed largely as drug classes are greater than specifying the discussed largely as drug classes are greater than specifying the discussed largely as drug classes are greater than specifying the discussed largely as drug classes are greater than specifying the discussed largely as drug classes are greater than specifying the discussed largely as drug classes are greater than specifying the drug drug classes are greater than specifying the drug drug drug drug drug drug drug drug													
Tesaro X X X X Tesaro X X X Tesaro X X X X Tesaro X X X X X Tesaro X X X X X X Tesaro X X X X X X X X X X X X X X X X X X X													
Tesaro X X X X S STATE S													
Tesaro X X X X Cell ovarian cancer; these will be discussed largely as drug classes rather than specifying individual products. A number of possible agents for investigation in the treatment of clear cell ovarian cancer; these will be discussed largely as drug classes as a cell ovarian cancer; these will be discussed largely as the discussed													
Novartis X Interest will be discussed largely as four classes rather than specifying individual products. A number of possible agents for investigation in the treatment of clear cell ovariant of clear cell ovariant of clear these will be discussed largely as well as generally as a cell ovariant of clear these will be discussed largely as a cell ovariant of clear than a cell ovariant of cell ovariant ovariant of cell ovariant of cell ovariant ovariant of cell ovariant ova						Tesaro	×	×	×				cell ovarian cancer;
rather than specifying individual products. A number of possible agents for investigation in the treatment of call ovariant and cancer; these will be discussed largely see a gent of the call ovariant of cancer and cance						IGSAIO	^	^	^				
individual products. A number of possible agents for investigation in the treatment of clear cell ovarian cancer; Novartis X these will be discussed largely as drug classes after than specifying at trug classes after than specifying at trug classes.													
A number of possible agents for investigation in the treatment of clear cell ovarian cancer; these will be discusses a rather than specifying													individual products.
Novartis X in the treatment of clear cell ovarian cancer; these with the set of the se													A number of possible
Novartis X cell ovarian cancer; these will be discussed largety classes rather than specifying													
Novariis A these will be discussed largely as drug classes of largely as pecifying after than specifying						Neventie							
rather than specifying						INOVAITIS			^				these will be discussed
fature individual products.													largely as drug classes
													individual products.

				Aprea			х				A number of possible agents for investigation in the treatment of clear cell ovarian cancer; these will be discussed largely as drug classes rather than specifying individual products.
				Clovis		x					A number of possible agents for investigation in the treatment of clear cell ovarian cancer; these will be discussed largely as drug classes rather than specifying individual products.
Guntupalli	Saketh	Invited Speaker/Faculty	Yes	Janssen Pharmaceuticals		X					
Hacker	Neville	Invited Speaker/Faculty	No								
Hamanishi	Junzo	Invited Speaker/Faculty	Yes	MSD			X				
		Session Moderator/Chair/Coordinator		Daiichi Sankyo		-	X	 	-	-	
				Ono			X				
Hanley	Sharon	Invited Speaker/Faculty	No								+
Hilpert	Felix	Invited Speaker/Faculty	Yes	AstraZeneca	X	X					
·port	· Silk	Committee (CME	.03	Tesaro	X	X					
Ishibashi	Tomoka	Invited Speaker/Faculty	No	100010							
Ishikawa	Mitsuya	Invited Speaker/Faculty	No								
Isonoshi	Seiji	Invited Speaker/Faculty Session Moderator/Chair/Coordinator	No								
Itamochi	Hiroaki	Poster/Oral Presenter	No								
Jhingran	Anuja	Invited Speaker/Faculty Poster/Oral Presenter	No								
Joura	Elmar	Invited Speaker/Faculty	Yes	Merck	Х	Х	X				
		Poster/Oral Presenter		Roche Diagnostics	X	X					
Kaneuchi	Masanori	Poster/Oral Presenter	No								
Katagi	Miho		No								
Kato	Shingo	Session Moderator/Chair/Coordinator	No								
Katsumata	Noriyuki	Invited Speaker/Faculty	No								
Kawana	Kei	Invited Speaker/Faculty Session Moderator/Chair/Coordinator	No								
Kim	Jae-Weon	Invited Speaker/Faculty	No								
Kim	Hee Seung	Invited Speaker/Faculty	No								
Kinnane	Nicole	Invited Speaker/Faculty	No								
Kurokawa	Tetsuji	Invited Speaker/Faculty	No								
Lai	Chyon-Huey	Scientific/Education Planning Committee Invited Speaker/Faculty Session Moderator/Chair/Coordinator	No								
Ledermann	Jonathan	Scientific/Education Planning Committee	Yes	AstraZeneca	Х	X	Х				+
_5404.	00.101.1011	Invited Speaker/Faculty		Pfizer	,	X	, n				
		Session Moderator/Chair/Coordinator		Clovis Oncology	Х	X					1
				Cristal Therapeutics		X					1
				Roche		X					
Lee Steele	Brenda	Invited Speaker/Faculty	No								
Leitao	Mario	Invited Speaker/Faculty Session Moderator/Chair/Coordinator	Yes	Intuitive Surgical	Х						
Levine	Douglas	Invited Speaker/Faculty	No								
Lheureux	Stephanie	Invited Speaker/Faculty	No								
Lurain	John	Invited Speaker/Faculty	No								
Lutman	Christopher	Invited Speaker/Faculty	Yes	CARIS Life Sciences	Х					CARIS Life Sciences	
				Clovis Oncology	Х					Clovis Oncology	
				Intuitive Surgical	Х					Intuitive Surgical	
Luvero	Daniela	Session Moderator/Chair/Coordinator	No								
Mabuchi	Seiji	Invited Speaker/Faculty Poster/Oral Presenter	No								

Mahantshetty	Llmanh	Scientific/Education Planning Committee	No			1	1	1		1		
Manantsnetty	Umesh	Invited Speaker/Faculty	NO									
Mariani	Andrea	Session Moderator/Chair/Coordinator	No									
Marth	Christian	Invited Speaker/Faculty	No									
Massuger	Leon	Invited Speaker/Faculty	No									
McAlpine	Jessica N.	Invited Speaker/Faculty	No									
McCormack	Mary	Poster/Oral Presenter Invited Speaker/Faculty	No									
	Iviary	Invited Speaker/Faculty							_			
McNally	Orla	Invited Speaker/Faculty Session Moderator/Chair/Coordinator	No									
McNeish	lain	Invited Speaker/Faculty	Yes	AstraZeneca		X	X					
						х					Cle	ovis
				Tesaro		X					Onc	ology
				Takeda		X						
Mellon	Anne	Invited Speaker/Faculty Session Moderator/Chair/Coordinator	No	ranoda								
Mikami	Mikio	Invited Speaker/Faculty	No									
Mileshkin	Linda	Invited Speaker/Faculty	No									
		Poster/Oral Presenter										
Mirza	Mansoor	Scientific/Education Planning Committee	Yes	Karyopharm Therapeutics		-		-	X	X		
		Invited Speaker/Faculty Session Moderator/Chair/Coordinator		Advaxis AstraZeneca	Х	X						
		Gession Moderator/Chair/Coordinator		Clovis Oncology	^	X						
				Tesaro		X				-		
				Roche	Х	^			-	+		
				TOOLG								
Mitamura	Takashi	Poster/Oral Presenter	No									
Miyagi	Etsuko	Invited Speaker/Faculty	Yes	Merck	Х		Х					
Monk	Bradley	Invited Speaker/Faculty	Yes	Abbvie	Х	X						
	,			Advaxis	Х	X						
				Amgen	Х	X						
				AstraZeneca	X	X						
				Biodesix	X	X						
				Clovis	X	X						
				Genmab	X	X						
				Gradalis	X	X						
				ImmunoGen	X	X						
				Immunomedics	X	X						
				Incyte	X	X						
				Janssen Pharmaceuticals	X	X						
				Mateon	X	X						
				Merck Myriad	X	X						
				Perthera	X	X						
				Pfizer	X	X						
				Precision Oncology	X	X						
				Puma	X	X						
				Genentech	X	X						
				Samumed	Х	Х						
				Takeda	X	Х						
				Tesaro	Х	X						
				VBL	X	X						
Moore	Kathleen	Invited Speaker/Faculty	Yes	Advaxis		X						
				AstraZeneca		X						
				Eli Lilly			X					
				Genentech		X						
				Janssen Pharmaceuticals		X		-				
				Merck		X		-				
Mories	Dhilinna	Invited Charles/Faculty	V	Tesaro		X						
Morice Morisada	Philippe Tohru	Invited Speaker/Faculty Poster/Oral Presenter	Yes No	Roche		X						
Morisada Nagasaka	Kazunori	Poster/Oral Presenter Invited Speaker/Faculty	No No									
	Satoru	Poster/Oral Presenter	No	Pfizer			X			-		
Nagase Ngan	Hextan	Invited Speaker/Faculty	No	FIIZEI			^					
Nishio	Shin	Invited Speaker/Faculty Invited Speaker/Faculty	No			-			-	+		
Nomura	Hiroyuki	Invited Speaker/Faculty Invited Speaker/Faculty	No			+		+	+	+		
· voiliulu	rinoyaki	Poster/Oral Presenter	110									

Nout	Remi	Invited Speaker/Faculty	No								
Nout	Keiiii	Session Moderator/Chair/Coordinator									
Oaknin	Ana	Session Moderator/Chair/Coordinator	Yes	AstraZeneca		X					
				Tesaro		X					
				Hoffmann-La Roche		X					
Oda	Mizue	Poster/Oral Presenter	No								
Oda	Katsutoshi	Invited Speaker/Faculty	No								
Ohno	Tatsuya	Invited Speaker/Faculty	No								
Okamoto	Aikou	Scientific/Education Planning Committee	Yes	Daiichi Sankyo			X				
		Session Moderator/Chair/Coordinator		Novartis			X				
				Pfizer			X				
Olawaiye	Alexander	Scientific/Education Planning Committee	Yes	Janssen Pharmaceuticals		X					
		Invited Speaker/Faculty		Tesaro							
Orango	Elkanah	Invited Speaker/Faculty	No								
ŭ	Omenge	, ,									
Orlandini	Elisa	Invited Speaker/Faculty	No								
Pareja	René	Session Moderator/Chair/Coordinator	No								
Pearl	Michael	Invited Speaker/Faculty	Yes	VitaTex			Х	X			
Plotti	Francesco	Session Moderator/Chair/Coordinator	No				1				
Power	Joanne	Invited Speaker/Faculty	Yes	AstraZeneca	Х	Х	1				
Pujade-	Eric	Invited Speaker/Faculty	Yes	AstraZeneca	X	X					
Lauraine	20	minos opositom addity		Hoffmann-La Roche	X	X					
Laa.anio				Pfizer		X					
				Tesaro	Х	X					
				Clovis		X					
				Galileo		X					
Puntambekar	Shaelish	Invited Speaker/Faculty	No	Gailleo		^					
Rimel	Bobbie		Yes	Tesaro		Х					
Killiei	Doople	Invited Speaker/Faculty	res	Genentech		X					
Sakamoto	Masaru	Invited Speaker/Faculty	No	Generitech		^					Clinical trial on safety
Sakamolo	Masaru	Session Moderator/Chair/Coordinator	NO								and efficacy of PDT using talaporfin sodium for CIN
Sato	Masakazu	Invited Speaker/Faculty	No								101 0114
Sato	Seiya	Poster/Oral Presenter	No								
Schmeler	Kathleen	Scientific/Education Planning Committee	No								
common.	rauiss.	Invited Speaker/Faculty Session Moderator/Chair/Coordinator Poster/Craft Presenter Committee (CME Research other)	0								
Scott	Clare	Invited Speaker/Faculty	Yes								pre-clinical use of PARF
		Session Moderator/Chair/Coordinator		AstraZeneca		X	х				inhibitors and eribulin ir ovarian cancer models
				Eisai						Research Collaboration, drug support	pre-clinical use of PARF inhibitors and eribulin in ovarian cancer models
				Clovis Oncology						Research Collaboration, drug support	pre-clinical use of PARF inhibitors and eribulin in ovarian cancer models
				Sierra Oncology			х				pre-clinical use of PARF inhibitors and eribulin in ovarian cancer models
				BeiGene						Research Collaboration, drug support	pre-clinical use of PARF inhibitors and eribulin in ovarian cancer models

				Roche						Research grant	pre-clinical use of PARF inhibitors and eribulin in ovarian cancer models
Seckl	Michael	Invited Speaker/Faculty Session Moderator/Chair/Coordinator	No								Pembrolizumab for treatment of GTN
Silva	Elvio	Invited Speaker/Faculty	No								
Silverberg	Steven G.	Invited Speaker/Faculty	No								
Simonds	Hannah	Scientific/Education Planning Committee Invited Speaker/Faculty Poster/Oral Presenter	No								
Singh	Naveena	Invited Speaker/Faculty Session Moderator/Chair/Coordinator Poster/Oral Presenter	No								
Slomovitz	Brian	Invited Speaker/Faculty	Yes	Advaxis		X					
				AstraZeneca		X					
				Janssen Pharmaceuticals		X					
				Tesaro		X					
Soliman	Pam	Invited Speaker/Faculty	Yes	Novartis			X				
				Janssen Pharmaceuticals		X					
				Clovis		X					
Soslow	Robert	Invited Speaker/Faculty Session Moderator/Chair/Coordinator	Yes	Springer Publishing Cambridge University Press				X			
				Jamasiago Cristoloxy 1 1000				,			
Stolnicu	Simona	Invited Speaker/Faculty	No								
Suzuki	Shiro	Invited Speaker/Faculty	No								
Suzuki	Nao	Invited Speaker/Faculty Session Moderator/Chair/Coordinator	No								
Suzuki	Miho	Invited Speaker/Faculty	No								
Takahashi	Kazuaki	Poster/Oral Presenter	No								
Takamatsu	Kiyoshi	Invited Speaker/Faculty	Yes	Bayer Otsuka Pharmaceutical Co., Ltd.						lecture fee	
				TSUMURA & Co.,						lecture fee	
Takano	Hirokuni	Invited Speaker/Faculty	No								
Takehara	Kazuhiro	Poster/Oral Presenter	No								
Takekuma	Munetaka	Invited Speaker/Faculty	No								
		Poster/Oral Presenter									
Tanaka	Yumiko	Invited Speaker/Faculty	No								
Terao	Yasuhisa	Poster/Oral Presenter	No								
Toita	Takafumi	Invited Speaker/Faculty	No								
Tsunoda	Audrey	Session Moderator/Chair/Coordinator Poster/Oral Presenter	Yes	Roche	Х						
Ueda	Masatsugu	Invited Speaker/Faculty	No								
Vergote	Ignace	Invited Speaker/Faculty	No								
Wakatsuki	Masaru	Invited Speaker/Faculty	No								
Westin	Shannon	Invited Speaker/Faculty	Yes	AstraZeneca		X	X			Clovis	bevacizumab bevacizumab
				Genentech		X					bevacizumab
				Merck		X	Х				bevacizumab
				Novartis		1	X				bevacizumab
				Tesaro		X	X				bevacizumab
				Bayer			X				bevacizumab
							х			Continga Pharmaceutical	bevacizumab
						X				Ovation	bevacizumab
						X				Medivation	bevacizumab
						X				Vermillion	bevacizumab
Wrede	David	Invited Speaker/Faculty	No							VOITIMION	DOVAGIZATIAD
Xiang	Yang	Invited Speaker/Faculty	No								
Yahata	Hideaki	Invited Speaker/Faculty	No								
Yamamoto	Eiko	Invited Speaker/Faculty	No								
	Kosuke	Invited Speaker/Faculty	No								